CollaGenex reiterated at outperform

RBC Capital Markets analyst Ken Trbovich gave CollaGenex Pharmaceuticals Inc. an outperform, speculative risk, rating and a $19 price target as IMS Health shows 3,545 Oracea prescriptions for the week ended Sept. 29, an increase of 10% over the prior week. The drug is still on track to meet the analyst's 14,000 prescriptions monthly estimate for October. RBC's model assumes that Oracea will reach about 6,500 prescriptions per week by December. Shares of the Newtown, Pa.-based specialty pharmaceutical company were up 27 cents, or 2.16%, at $12.77. (Nasdaq: CGPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.